GP96 Heat Shock Protein-Peptide Complex Vaccine in Treating Patients With Liver Cancer
- Conditions
- Liver Cancer
- Interventions
- Biological: gp96
- Registration Number
- NCT04206254
- Lead Sponsor
- Cure&Sure Biotech Co., LTD
- Brief Summary
This trial is to further study the safety and effectiveness of autologous gp96 treatment of liver cancer on the basis of preliminary work
- Detailed Description
RATIONALE: heat shock protein gp96-peptide complex made from a person's tumor cells may help the body build an effective immune response to kill tumor cells.
Overall Goals:
- to evaluate the safety and induction of anti-tumor immunity by administration of an immunogenic human tumor cell vaccine, and assess immune response in relation to clinical outcome.
Primary Aim:
- to further evaluate effectiveness of autologous gp96 treatment of liver cancer on the basis of preliminary work.
Secondary Aims:
to study the immune response to vaccination, to monitor clinical responses , to further the safety of vaccine.
Recruitment & Eligibility
- Status
- UNKNOWN
- Sex
- All
- Target Recruitment
- 80
- Able to read and understand the informed consent document; must sign the informed consent;
- Aged 18 to 75 years old , sex is not limited;
- must have undergone radical resection;AJCC TNM II、III、IV.
- Availability of at least 1g tumor sample;
- Adequate bone marrow function including the absence of lymphopenia (ANC > 1,500/ mm3; Hemoglobin > 10g/dL ; platelet count >100,000/mm3), adequate liver function (serum glutamic oxaloacetic transaminase/ aspartate aminotransferase [AST], alanine amino transferase [ALT] <2.5 times institutional upper limit of normals [IULNs] ), and adequate renal function (BUN and creatinine <1.5 times IULNs)
- Agree to Surgical indications of Heart & lung and without the coagulation system disease
- Patients could not have received previous anti-cancer treat before 4 weeks of gp96 treatment；
- Inability to comply with study-related procedures
- Unavailability of at least 6 doses of vaccine
- Severe allergies
- Unstable or severe intercurrent medical conditions
- Current diagnosis of Human Immunodeficiency Virus and Patients with active uncontrolled infection.
- patients with any systemic disease needed to be treated with immunosuppressant or Corticosteroids.
- Female patients who are pregnant or breastfeeding
- Steroidal drugs are currently being used systemically.
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description gp96 group gp96 Patients only receive autologous gp96 vaccination after surgery (do not accept other anti-tumor treatments) 6 times of gp96 vaccination are administered via subcutaneous injection in 25μg doses within 8 weeks after surgery. gp96 is administered once a week.
- Primary Outcome Measures
Name Time Method 2-year recurrence-free survival rate 2 year
- Secondary Outcome Measures
Name Time Method Disease free survival 5 year changes in antigen specific T cells within 3 days before the first vaccination and within 10 days after the last vaccination tumor antigen specific T cells are determined by IFN-γ Enzyme-linked Tumor antigen specific T cells will be determined by IFN-γ Enzyme-linked immunosorbent spot using the autologous tumor cell lysis as the antigen
Number of participants with adverse events related to gp96 immunotherapy up to 3 months after vaccine completion A complete blood count will be requested before the first vaccination, after the second vaccination and after the last vaccination to monitor the side effect of gp96 immunotherapy. And blood chemistries will also be requested at the same time point for the same reason.And other adverse events related to gp96 immunotherapy will be recorded according to the NCI-CTCAE 5.0 criteria.
Overall survival 5 year